Sign Up | Log In | What is SocialPicks?

Investment Ideas Served Daily By People You Trust

SocialPicks is a community where stock investors exchange ideas and track performance of financial bloggers.

Are you a stock guru?

Share picks & earn reputation

jmho

Start Tracking jmho - Add to Friends - Send Message

Community Rank: Analyst (199 pts) | Member since 02/13/2007

Picks Performance:

Outperforms

52%

of community

What's this?

All-time Return +1.29% (in over 3 years)	Risk (SD) Aggressive 0.00%	Sharpe Ratio -14.32
Followers 0	Winning Picks 5 of 15	Total Views 4523

Overview

Stocks

Stats

Community

Widget

Last Activity: Added BA to bullish list on 12/06/07

Current Stock List:

Symbol	SP Sentiment	Return	Since
BA		-23.43%	12/06/07
NMX		n/a	12/06/07
ARNA		-63.89%	12/06/07
FMD		+82.98%	12/06/07
GENZ		-18.61%	12/06/07
GOOG		-21.49%	12/06/07
ALTU		n/a	02/15/07
ERTS		-62.93%	02/13/07
MLNM		+100.00%	02/13/07
SHG	N/A	-35.31%	02/13/07

All-time Sectors of Interest

... View All >

Opinion & Analysis

Genzyme (GENZ) stock breaks out on good news about GENZ 12/06/07
Genzyme ( GENZ ) saw its shares break out last week from $62.5 to over $68 on higher than average volume. The weekly chart below demonstrates this movement and its significance as it broke a long ...

... View All >

Blog Posts

AMGN VRTX Decoupled moves in Biotech indices highlight opportunities and challenges 07/25/09 — The chart below shows returns for the last 6 months of the two Biotech indices that I follow: BTK and NBI.After a significant and equivalent downside move in March, both indices have turned positive with an explosive move since middle of July. I speculate that the March downside move was a response ...

Read 0 comments

AMGN JNJ Rigel's Phase II Rheumatoid Arthritis drug data are good but financing remains a challenge 07/11/09 — On July 9th, Rigel Pharmaceuticals (RIGL) announced the results of TASKi2, a 457 patient Phase IIb Rheumatoid Arthritis study that in most part showed R788 ( a Syk kinase inhibitor) has efficacy similar to existing injectable anti-TNF medications (although it was not a head-to-head comparison). Ther...

Read 0 comments

DNA AMGN Celgene (CELG) is a bargain once again 09/19/08 — The latest crash of the financial markets has created some great buying opportunities in the health care sector. You can almost pick any Biotechnology or Pharmaceutical stock and be guaranteed that it is undervalued today. The sell-off was steep and broad and took down good stocks with the bad. I...

Read 0 comments

LLY AMLN Byetta may not be the cause of recent deaths, stock reaction unjustified 08/27/08 — On Tuesday August 26, Amylin (AMLN) and its partner Eli Lilly (LLY) announced that four patients had died while on diabetes treatment Byetta.Both Amylin (down 12%) and Lilly (down 1%) sold off in after hours following repeated headlines saying Byetta responsible for death.The truth is no one knows w...

Read 0 comments

AMGN ALNY Performance of Biotechnology Stock Blog Portfolio 08/13/08 — Analyzing the performance of my previous picks is by far my favorite part of writing this blog. It has on many occasions allowed be to learn from my mistakes.I have moved the numbers to Google docs so that they are easier to read. Here is a link to that spreadsheet.The bottom line return for this por...

Read 0 comments

... View All >

Discussions

jmho hasn't participated in any discussions yet.

People Following jmho ...

Nobody is following jmho.

Similarity to Me ?

Compare Your Portfolio With jmho: Enter stocks you like & get new ideas daily:

Symbols, separated by space (e.g. AAPL GOOG MSFT)

More about jmho

Avg exp holding time:
951.32 days

Similar Portfolios

Marian Filo (supratrade) 62% 70%

Jim Cramer (trackjimcramer_bloggingstocks) 42% 41%

mlgeorge (mlgeorge) N/A 41%

Mike Havrilla (mikehav) 73% 35%

william0509 (william0509) 67% 35%

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.